Positioning political selling, disclosed 2026-09-24
Options put/call open interest 1.38, read 2026-11-05
Ethical passes the values gate
Price227.11 USD
Fair value350.80
Ethical score86.8/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-11-01Read Distribution229.17-0.9% to today ✓Accumulation gives way to Distribution after a 7% slide in 2 weeks
2026-10-18Read Accumulation246.74-8.0% to today Distribution gives way to Accumulation after a 5% rise in 2 weeks
2026-10-02Read Distribution234.02-3.0% to today ✓Markup gives way to Distribution after a 26% rise in 13 weeks
2026-07-02Read Markup185.66+22.3% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Salesforce holds its Distribution at $227.11. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-11-04
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$227.11
Valuation
21.13 trailing · 14.41 forward price to earnings
Values screen
PASS· score 86.8
Beta
1.26
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
15.29%
Below 33%
Interest-bearing debt is just 15.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
6.72%
Below 33%
Cash held in interest-bearing accounts and securities is 6.7% of assets, under the one-third limit.
Pass
Receivables
19.29%
Below 49%
Money owed to the company is 19.3% of assets, under the 49% limit.
Pass
Revenue purity
1.30%
Below 5%
Only 1.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Salesforce clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 15%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CRM's ethical verdict changes
Today CRM passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Conscience flag · Employee campaigns, BDS Movement
The quantitative screen above is arithmetic and this name passes it. Separately, community boycott lists cite this company: Cited in employee-led campaigns for technology contracts with Israeli government entities. Internal employee petitions raised concerns about use of Salesforce products. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 35% discount to our $350.80 fair value, moderate competitive moat, 10.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 35.3% discount to the base estimate.
Where our models see it going: fair-value estimate $350.80, with a range of $312.45 to $454.22, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
A 11%-growth business trading at just 14.4x forward earnings, with a moderate competitive moat. That is a 35% discount to our $350.80 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 53 analysts rate it Buy with a $285.00 average target, about 25% above the screened price.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRM trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262.
2026-10-25Accumulation$246.74+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262.
2026-10-11Distribution$234.02+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 13.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262.
2026-08-26Markup$205.43+0.0%Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup$205.43+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Markup$205.43+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Markup$205.43+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Markup$205.43+0.0%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 36%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (53 analysts) rates it buy, with a mean price target of $262. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
